Everything below concerns bremelanotide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
| Property | Value | Notes |
|---|---|---|
| Storage form | Lyophilized powder | Longer stability at -20 °C |
| Reconstitution solvent | Sterile water or buffer | Depends on intended application |
| Purity assessment | Reverse-phase HPLC | Reported as peak area percentage |
| Identity confirmation | Mass spectrometry | Compared against theoretical mass |
| Main stability concern | Repeated freeze-thaw | May promote aggregation |
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
==== Diet ==== In addition to increased fluid intake, breastfeeding women need additional calories to support milk production. This is estimated to be upwards of 300 calories per day. Mercury in fish is an important consideration for breastfeeding women. Though fish can be a good protein source, fish also contain mercury, which can be harmful. The concentration of mercury varies by fish species.
Individuals, particularly children experiencing abuse, may feel a loss of control over their life, circumstances, and their own bodies. Particularly sexual abuse, but also physical abuse, can make individuals feel that the body is not a safe place and an object over which another has control. Starvation, in the case of anorexia, may also lead to reduction in the body as a sexual object, making starvation a solution. Restriction may also be a means by which the pain an individual is experiencing can be communicated.
The region is 1,200 kilometres (750 mi) from the sea and has an arid continental climate on the north to humid continental climate to the south, with average summer temperatures rising to 17 to 24 °C (63 to 75 °F) in July and average winter temperatures dropping to between −7 and −15 °C (19 and 5 °F) in January. Seasonal extreme temperatures can reach 39 °C (102 °F) in summer and −30 °C (−22 °F) in winter. The diurnal temperature variation can reach above 17 °C (31 °F), especially in spring. Annual rainfall averages from 190 to 700 millimetres (7.5 to 27.6 in), with more rain falling in the south of the region.
=== Unsaturated thiols === Vinyl thiols are rare, but other unsaturated thiols are numerous. A textbook unsaturated thiol is grapefruit mercaptan, which exists as two enantiomers, each with distinct odors. The main component of skunk spray is a butenylthiol.
Sources: en.wikipedia.org
Nicotiana tabacum, or cultivated tobacco, is an annually grown herbaceous plant of the genus Nicotiana. N. tabacum is the most commonly grown species in the genus Nicotiana, as the plant's leaves are commercially harvested to be processed into tobacco for human use. The plant is native to Bolivia, commonly grown throughout the world and often found in cultivation. It grows to heights between 1 and 2 metres (3.3 and 6.6 ft). Research is ongoing into its ancestry among wild Nicotiana species, but it is believed to be a hybrid of Nicotiana sylvestris, N. tomentosiformis, and possibly N. otophora.
=== Legal status === Risperidone was approved by the United States Food and Drug Administration (FDA) in 1993 for the treatment of schizophrenia. In 2003, the FDA approved risperidone for the short-term treatment of the mixed and manic states associated with bipolar disorder. In 2006, the FDA approved risperidone for the treatment of irritability in autistic children and adolescents. The FDA's decision was based in part on a study of autistic people with severe and enduring problems of violent meltdowns, aggression, and self-injury; risperidone is not recommended for autistic people with mild aggression and explosive behavior without an enduring pattern. On 22 August 2007, risperidone was approved as the only drug agent available for the treatment of schizophrenia in youths, ages 13–17; it was also approved that same day for the treatment of bipolar disorder in youths, ages 10–17, joining lithium. In December 2021, the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended market authorization for Okedi, a long-acting depot injection of risperidone. Okedi was approved for the treatment of schizophrenia in adults for whom the tolerability and effectiveness of risperidone had already been established using an oral formulation. Long-acting depot injectable risperidone was approved for medical use in the European Union in February 2022.
Superman ice cream is a three-flavor ice cream that usually appears in red, blue, and yellow. The flavor originated in the Midwestern United States, seen frequently in Michigan, Wisconsin, and Ohio. It can also be found in various ice cream parlors across the United States. Although the flavor originated before the debut of Superman in 1938, it became associated with him due to his matching costume colors. As the character's name was never officially licensed, most producers sell the flavor under different brand names to avoid potential trademark or copyright issues. The exact flavor mixture is not as well defined as the color scheme, and different brands often vary the flavor components used to make up the swirl. Many of the traditional versions call for Blue Moon as the blue component of the swirl. Blue Moon has a hard-to-place flavor and, like the Superman flavor which often incorporates it, was created in the early 20th century. The Blue Moon flavor can also be found around the United States in ice cream parlors which serve Hershey's ice cream, as well as select grocery stores and gas stations. The combination is commonly believed to have originated in Detroit, Michigan, at Stroh's Ice Cream during the Prohibition Era, but this is unconfirmed.
== Promotions == Runza is a vendor in Memorial Stadium, home of the Nebraska Cornhuskers football team, In 2017, the Omaha Storm Chasers, Omaha's Triple-A affiliate of the Kansas City Royals Major League Baseball team, rebranded themselves as the "Omaha Runzas" in a cross-promotional event. The team's rebranded uniforms featured a cartoon runza sandwich and shared the green and yellow livery of the Runza restaurant chain. Runza operated a 1950s themed Rock n' Roll Runza featuring memorabilia, vintage automobiles and roller skating carhops out of downtown Lincoln from 1991 to 2004.
The new department was financed by a US $12-million gift from Bill Gates, who shared Hood's interest in combining biological research and computer technology and applying them to medical research. Roger Perlmutter, who had worked in Hood's lab at Caltech before moving to UW as chair of the immunology department, played a key role organizing his recruitment to UW. Hood and other scientists from Caltech's NSF center moved to the University of Washington during 1992-1994, where they received renewed support from the NSF as the Center for Molecular Biotechnology. (Later, in 2001, the department of molecular biotechnology and the genetics department at UW reorganized to form the department of genome sciences.) In 2000 Hood resigned his position at the University of Washington to become co-founder and president of the non-profit Institute for Systems Biology (ISB), possibly the first independent systems biology organization. His co-founders were protein chemist Ruedi Aebersold and immunologist Alan Aderem. Hood is still an affiliate professor at the University of Washington in Computer Science, Bioengineering and Immunology. In April 2017, the ISB announced that Hood will be succeeded as president of ISB as of January 2018 by James Heath, while continuing to lead his research group at ISB and serving on ISB's board of directors. Hood believes that a combination of big data and systems biology has the potential to revolutionize healthcare and create a proactive medical approach focused on maximizing the wellness of the individual. He coined the term "P4 medicine" in 2003.
Sources: en.wikipedia.org
Storage at -20 °C or below is standard for long-term stability. Desiccant and sealed containers limit moisture exposure. Solutions are prepared only when needed.
Reverse-phase HPLC separates components by hydrophobicity and reports purity as a percentage of total peak area. It does not by itself confirm molecular identity. Mass spectrometry is used alongside it for that purpose.
They link a specific lot to its analytical results and storage history. This traceability supports reproducibility when results differ between experiments. Records also help identify when re-testing is warranted.
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.